Primary IOL implantation relatively safe for infant aphakia

Article

It is relatively safe and effective for infants to undergo primary IOL implantation for the correction of aphakia after having one cataract removed, according to new research out of China.

It is relatively safe and effective for infants to undergo primary IOL implantation for the correction of aphakia after having one cataract removed, according to new research out of China. Press-on spherical lenses are options for those unsuited to IOLs implantation add the investigators in an article appearing in Acta Ophthalmologica.

The study authors performed unilateral cataract extraction on 60 infants and then randomly assigned some of them to undergo IOL implantation and have any residual refractive error corrected with eyeglasses. Those patients not receiving IOLs were treated with press-on spherical lenses. The investigators measured grated visual acuity (VA) and followed the patients for up to a year.

All infants experienced better LogMAR VA in their operated eyes at 1 year compared with 1 month after surgery, although those receiving IOLs saw greater improvement. Those undergoing lens implantation also were more likely to experience serious inflammation, however, as well as visual axis opacity.

The prevalence of glaucoma was the same in both groups. There were no other complications.

To read an abstract of the study, visit the journal's website.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.